London, Jan 11, 2026, 09:07 GMT — Market closed.
- Smith & Nephew shares ended Friday down 0.9% in London.
- CEO Deepak Nath is due to speak at the JPMorgan Healthcare Conference on Monday.
- Investors are looking for fresh clues ahead of full-year results on March 2.
Smith & Nephew (SN.L) heads into the new week with a near-term catalyst on the calendar: CEO Deepak Nath is set to present at the JPMorgan Healthcare Conference on Monday. The stock closed on Friday at 1,258 pence, down 0.9%. (Smith & Nephew)
That matters because the broader tape was upbeat into the weekend. London’s FTSE 100 closed at a record high on Friday, lifted by a jump in Glencore and a U.S. jobs report that kept rate-cut bets alive. (Reuters)
Healthcare did not lead the move. Market summaries of Friday’s session showed the sector lagging even as energy and mining stocks pushed the main index higher. (Trading Economics)
For Smith & Nephew holders, the Monday slot is less about charts and more about wording. Investors will look for any shift on procedure demand, pricing and cost control — the things that tend to land first in conference remarks.
The next hard checkpoint comes later: Smith & Nephew has said it will release full-year results on March 2. That’s when it is expected to put formal numbers around 2026 after a run of provisional targets. (Smith & Nephew)
In December, the company rolled out its “RISE” strategy and set 2028 targets that imply faster growth. Nath called it “an ambitious but achievable new chapter,” as the group laid out goals including a 6%-7% underlying revenue CAGR (growth rate that strips out currency swings and deal effects) and more than $1 billion of free cash flow (cash left after running costs and investment) in 2028. (Smith & Nephew)
Some analysts have pushed back on how steep that step-up looks from past performance. “Given the significant step up from historical performance required to achieve this target, we remain nervous until the company can demonstrate reliably that it can generate this growth,” RBC Capital Markets analyst Jack Reynolds-Clark told Reuters at the time. (Reuters)
The sensitive spot remains orthopaedics, especially knees in the United States. In November, Smith & Nephew missed quarterly revenue expectations as U.S. knee implant sales lagged, a reminder that the turnaround pitch still hangs on execution in a mature, competitive market. (Reuters)
Rivals are not standing still. Smith & Nephew competes with groups such as Stryker and Zimmer Biomet in orthopaedics, and with Johnson & Johnson’s DePuy Synthes across implants and surgical kit — businesses where pricing, hospital budgets and operating-room time matter as much as product cycles.
But Monday’s conference appearance is not earnings, and it can cut both ways. If management leans cautious on U.S. knees, flags slower procedure volumes, or sounds less firm on margin improvement, traders can mark shares down quickly — especially after a risk-on Friday that left defensives behind.
